<DOC>
	<DOC>NCT01872182</DOC>
	<brief_summary>The main objective of this study is to evaluate efficacy and safety of ALS-L1023 tablet in patients with abdominal obesity of metabolic syndrome.</brief_summary>
	<brief_title>Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Obesity, Abdominal</mesh_term>
	<criteria>Aged between 20 and 64 years(Both genders) more than 2 among components of the metabolic syndrome Triglyceride &gt;= 150mg/dL HDLD: Women &lt; 50mg/dL or Men &lt; 40mg/dL Hypertension: Systolic blood pressure &gt;= 130mmHg or Diastolic blood pressure &gt;= 85mmHg Hyperglycemia: fasting plasma glucose &gt;= 100 mg/dL Informed consent awarding Alcohol or any drug abuse Any investigational medication during the preceding 3 months</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>